Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE)

Historical Holders from Q3 2014 to Q3 2025

Symbol
SAGE
CUSIP
78667J108
Type / Class
Equity / Common Stock, par value $0.0001 per share (the "Common Stock")
Shares outstanding
62.7M
All holders as of June 30, 2025
Q2 2025
Total 13F shares, excl. options
48.9M
Holdings value
$446M
% of all portfolios
0.004%
Grand Portfolio weight change
0%
Number of holders
190
Number of buys
97
Number of sells
-95
Average Value change %
+0%
Average buys %
+0.002%
Average sells %
-0.002%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Madison Avenue Partners, LP 9.7% +21.3% $52.7M $10M 6.08M +23.5% Madison Avenue Partners LP Jun 30, 2025
BlackRock, Inc. 7.2% $30.6M 4.43M BlackRock, Inc. Mar 31, 2025
VANGUARD GROUP INC 5.21% -33.6% $25.4M -$12.2M 3.27M -32.5% The Vanguard Group Jun 30, 2025
RTW INVESTMENTS, LP 4.9% $20.7M 3M RTW Investments, LP Dec 31, 2024
BB BIOTECH AG 1.9% $8.14M 1.18M BB Biotech AG Jan 13, 2025
MORGAN STANLEY 1.6% -82.9% $7M -$24.4M 1.01M -77.7% Morgan Stanley Feb 28, 2025
FMR LLC 0.8% -84.3% $3.46M -$25M 501K -87.8% FMR LLC Feb 28, 2025

Institutional Holders of Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 0 $0 -$1.72K 0
2025 Q2 48.9M $446M -$14.7M $9.12 190
2025 Q1 51.8M $411M +$29.1M $7.95 196
2024 Q4 51.2M $278M -$6.2M $5.43 173
2024 Q3 51.3M $370M -$24.5M $7.22 172
2024 Q2 53.5M $581M -$65.1M $10.86 191
2024 Q1 58.2M $1.09B +$31.2M $18.74 197
2023 Q4 71K $1.55M -$3.11M $21.67 3
2023 Q3 58.2M $1.2B -$2.92M $20.58 186
2023 Q2 53.4M $2.51B +$37.8M $47.02 218
2023 Q1 52.7M $2.21B +$61.6M $41.96 207
2022 Q4 51.6M $1.97B +$2.02M $38.14 197
2022 Q3 45M $1.76B +$7.13M $39.16 177
2022 Q2 50.4M $1.63B +$35.1M $32.30 182
2022 Q1 49.3M $1.63B -$34.5M $33.10 184
2021 Q4 44.7M $1.9B +$38.9M $42.54 196
2021 Q3 49M $2.17B -$111M $44.31 214
2021 Q2 50.4M $2.86B -$183M $56.81 248
2021 Q1 53.1M $3.97B -$90.5M $74.85 255
2020 Q4 53.4M $4.62B +$45.1M $86.51 240
2020 Q3 53.5M $3.27B -$23.4M $61.12 218
2020 Q2 53.7M $2.24B +$1.23M $41.58 202
2020 Q1 54.9M $1.58B -$221M $28.72 206
2019 Q4 55.6M $4.01B -$406M $72.19 250
2019 Q3 58.2M $8.16B +$20.7M $140.29 269
2019 Q2 58M $10.6B +$1.07B $183.09 260
2019 Q1 55.9M $8.89B +$1.1B $159.05 253
2018 Q4 49.7M $4.76B +$6.32M $95.79 236
2018 Q3 48.7M $6.87B +$63.1M $141.25 269
2018 Q2 48.4M $7.57B +$240M $156.53 262
2018 Q1 47.4M $7.63B +$643M $161.07 242
2017 Q4 44M $7.25B +$674M $164.71 217
2017 Q3 39.3M $2.45B +$48.6M $62.30 168
2017 Q2 38.4M $3.06B +$15.1M $79.64 187
2017 Q1 37.9M $2.69B +$271M $71.07 184
2016 Q4 36.7M $1.88B -$47.8M $51.06 160
2016 Q3 37.8M $1.74B +$399M $46.05 149
2016 Q2 30.2M $911M +$29M $30.13 137
2016 Q1 29.1M $932M +$174M $32.06 138
2015 Q4 23.5M $1.37B +$159M $58.30 133
2015 Q3 27.2M $1.15B +$22.8M $42.32 125
2015 Q2 26.3M $1.92B +$371M $73.00 120
2015 Q1 21.5M $1.08B +$66.6M $50.23 89
2014 Q4 19.7M $721M +$20.8M $36.60 70
2014 Q3 18.9M $595M +$595M $31.50 50